New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
March 2, 2015
16:26 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
12:13 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
11:52 EDTJNJJohnson & Johnson EPS dilution from Cordis deal seems modest, says Wells Fargo
Wells Fargo estimates that Johnson & Johnson's (JNJ) planned sale of Cordis to Cardinal Health (CAH) should dilute J&J yearly EPS by about 3c-4c, assuming all is else equal, and the firm expects the company to be able to absorb at least some of this dilution and possibly offset the rest via share repurchases. Wells maintains its Outperform rating on J&J shares.
09:28 EDTBMYBristol-Myers says FDA accepts Yervoy sBLA for review
Subscribe for More Information
08:01 EDTJNJCardinal Health offers to buy Cordis from Johnson & Johnson in $1.99B deal
Subscribe for More Information
07:53 EDTJNJCardinal Health to host conference call
Subscribe for More Information
07:35 EDTJNJCardinal Health to buy Cordis from Johnson & Johnson in $1.99B deal
Subscribe for More Information
07:35 EDTJNJCardinal Health to acquire Cordis for $1.94B in cash
Cardinal Health (CAH) announced plans to acquire Johnson & Johnson's (JNJ) Cordis business, a global manufacturer of cardiology and endovascular devices, for $1.94B in cash, or approximately $1.59B, net of the present value of tax benefits. The acquisition is expected to be financed with a combination of $1B in new senior unsecured notes and the remainder with existing cash. The transaction is expected to close in the United States and key non-U.S. countries towards the end of calendar 2015. Assuming this timing, Cardinal Health expects fiscal 2017 accretion in non-GAAP diluted earnings per share from continuing operations of greater than 20c per share, which includes the cost of an incremental 7c-8c per share of interest expense associated with financing the transaction. The company expects the acquisition to be increasingly accretive thereafter and assumes that synergies will exceed $100M annually by the end of fiscal 2018. Cordis had annual sales in 2014 of approximately $780M, split almost evenly between cardiology and endovascular products. Upon completion of that process, Cardinal Health expects to enter into a definitive purchase and sale agreement in respect of the proposed acquisition. The proposed transaction will also be subject to customary closing conditions, including regulatory approvals, and is expected to close in the approximately 20 principal countries towards the end of calendar year 2015 and in the remaining countries on a rolling basis afterward.
07:20 EDTBMYCowen to hold a conference
Subscribe for More Information
February 27, 2015
17:56 EDTHESHess Corp. files automatic mixed securities shelf
Subscribe for More Information
16:22 EDTJCPStocks have another winning week after Greek deal, Yellen reassurance
Stocks ended higher this week after the euro zone sealed its deal to extend Greece's bailout and Fed chair Janet Yellen reiterated that the central bank would take a patient approach to raising interest rates. MACRO NEWS: Last Friday afternoon, Greece reached a framework deal with its euro zone partners to extend its bailout by four months, contingent on a reform proposal being accepted. The proposals were accepted by the EU early this week... In testimony before Congress, Janet Yellen reiterated that the Federal Reserve can remain patient in deciding when to hike interest rates... U.S. economic data was mixed, as the Q4 GDP growth revision, durable goods orders for January, and an index of consumer sentiment beat expectations, but weekly jobless claims and existing home sales for January missed expectations... Somewhat positive economic data came out of China, as the flash HSBC/Markit Purchasing Managers' Index was 50.1, representing a four month high. However, China's export orders declined at the fastest rate in 20 months. COMPANY NEWS: Drug maker Valeant (VRX) agreed to buy Salix (SLXP), which develops gastrointestinal products, for $158 per share. In another development on the M&A front, Bloomberg reported that HP (HPQ) is in talks to make its biggest acquisition in several years by potentially acquiring Aruba Networks (ARUN), which provides Wi-Fi products. Additionally, PTC Therapeutics (PTCT) rose after Reuters said the company is working with financial advisers to explore a potential sale after receiving takeover interest from several companies including Shire (SHPG) and BioMarin (BMRN)... Solar energy company SunPower (SPWR) was one of this week's big winners after its quarterly results topped expectations, and the company announced that it's in advanced talks to form a joint YieldCo vehicle with peer First Solar (FSLR). First Solar also rallied after the news... Among the noteworthy losers this week was Lumber Liquidators (LL), after the company reported Q4 earnings per share and revenue that missed consensus expectations. The flooring retailer also warned on its associated call that an upcoming "60 Minutes" piece may cast the company in an unfavorable light and disclosed in its annual report that the Department of Justice indicated in recent communications that it is contemplating seeking criminal charges under the Lacey Act... Companies that rose after reporting their quarterly results included Home Depot (HD) and Gap (GPS), while HP, TASER (TASR), and J.C. Penney (JCP) dropped after reporting their results. INDEXES: For the week, the Dow was down 0.04% to 18,132.70, the Nasdaq was up 0.15% to 4,963.53, and the S&P 500 was down 0.27% to 2,104.50.
16:14 EDTJCPOn The Fly: Closing Wrap
Stocks on Wall Street were lower for the day, but still rose for the week and the month of February. The market moved in a narrow range for most of today's session despite a host of economic reports that were released earlier in the day. In spite of today's modest declines, the market put the finishing touches on one of its best months ever, with the Dow and S&P posting their best monthly rises since October 2011 and the Nasdaq notching its best month since 1998. ECONOMIC EVENTS: In the U.S., the Commerce Department estimated GDP grew at an annual rate of 2.2% in the last quarter of 2014, which is weaker than the 2.6% rate first estimated last month, but above the consensus forecast for the GDP growth rate to be cut to 2%. The Chicago PMI fell 13.6 points to 45.8 in February, which was much worse than the expected reading of 58.0. The University of Michigan consumer sentiment final February print came in at 95.4, which is a little better that the 93.6 preliminary February print and above the consensus forecast for a 94.0 reading. The pending home sales index bounced 1.7% to 104.2 in January, versus expectations for it to be up 2%. COMPANY NEWS: Two notable retailers moved in opposite directions following their quarterly reports, as Gap (GPS) rose and J.C. Penney fell. Gap gained $1.23, or 3.05%, to $41.60 after the company reported fourth quarter earnings that beat expectations. The owner of Old Navy, Banana Republic and its flagship nameplate also announced a $1B share repurchase program and plans to increase its dividend. J.C. Penney, meanwhile, reported earnings that missed expectations and gave a 2015 gross margin outlook that disappointed some analysts and its shares slid 62c, or 6.8%, to $8.50. MAJOR MOVERS: Among the notable gainers was Monster Beverage (MNST), which jumped $16.38, or 13.13%, to $141.12 after the energy drink maker's fourth quarter results surpassed analysts’ consensus estimates and announced plans to expand distribution with Coca-Cola (KO) bottlers into additional territories. Among the noteworthy losers was Weight Watchers (WTW), which dropped $6.23, or 35.48%, to $11.33 after reporting lower than expected quarterly revenues and issuing a worse than expected profit forecast for its new fiscal year. Also lower were shares of Southwestern Energy (SWN), which fell $1.27, or 4.82%, to $25.08 after becoming the latest oil production company to lower its 2015 capital expenditure forecast. INDEXES: The Dow fell 81.72, or 0.45%, to 18,132.70, the Nasdaq lost 24.36, or 0.49%, to 4,963.53, and the S&P 500 declined 6.24, or 0.3%, to 2,104.50.
14:34 EDTJNJPharmacyclics says Imbruvica combination enhances anti-tumor activity
Subscribe for More Information
13:35 EDTBMYBristol-Myers reports FDA accepts BLA for Opdivo
Subscribe for More Information
12:54 EDTJCPOn The Fly: Midday Wrap
Subscribe for More Information
11:04 EDTJCPStocks with call strike movement; JCP DDD
J.C. Penney (JCP) August 10 call option implied volatility decreased 5% to 44, 3D Systems (DDD) August 34 call option implied volatility increased 7% to 44 according to IVolatility.
09:37 EDTJCPJ.C. Penney tumbles, levels to watch
Subscribe for More Information
09:24 EDTJCPOn The Fly: Pre-market Movers
Subscribe for More Information
09:23 EDTJCPJ.C. Penney 2017 financial targets are unattainable, says Craig-Hallum
Craig-Hallum said J.C. Penney's 2015 gross margin outlook supports its view the company's 2017 financial targets are unattainable. Given the continued double digit growth of the margin dilutive e-commerce channel, the firm does not see meaningful upside to gross margin targets and reiterates Sell rating.
08:29 EDTBMYBristol-Myers price target raised to $78 from $70 at Argus
Subscribe for More Information
08:15 EDTJNJJohnson & Johnson would benefit from Pharmacyclics deal, says Wells Fargo
After Bloomberg and The Financial Times reported that Johnson & Johnson (JNJ) and Novartis (NVS) are interested in buying Pharmacyclics (PCYC), Wells Fargo thinks the deal would cause a slight acceleration of Johnson & Johnson's revenue growth. The firm believes that the deal could be slightly dilutive to Johnson & Johnson's EPS in the first full year and 1%-4% accretive thereafter. Wells keeps an Outperform rating on Johnson & Johnson.
07:11 EDTJCPJ.C. Penney remains a 'show me story,' says Deutsche Bank
Subscribe for More Information
06:46 EDTJCPJ.C. Penney sell-off a buying opportunity, says Piper Jaffray
Subscribe for More Information
February 26, 2015
18:43 EDTJCPOn The Fly: After Hours Movers
Subscribe for More Information
17:55 EDTJCPJ.C. Penney sees Q1 sales to be impacted less than 1% due to West Coast ports
Management stated that they believe that the West Coast port shutdown impacted holiday business. The company did see a slowdown in January and ended FY14 $30M-$50M lower than was expected. The company is attempting to leverage other ports on the East Coast and Gulf Coast. The company is mitigating late shipments by transporting more goods via roadway than by rail. The company expects Q1 sales to be impacted less than 1% and Impacts to gross margins to be less than $20M. Both the Q1 sales and Q1 gross margin impact is accounted for in the company's FY15 guidance.
17:35 EDTJCPJ.C. Penney CEO Ullman says company is 'back and competing effectively'
Subscribe for More Information
17:25 EDTJCPJ.C. Penney reports men's apparel, home, fine jewelry were top performers in Q4
Subscribe for More Information
17:21 EDTJCPJ.C. Penney reports FY14 positive free cash flow of $57M
Subscribe for More Information
16:52 EDTIQNTOn The Fly: Closing Wrap
Stocks on Wall Street moved in a narrow range for most of the session while remaining near record levels. The Nasdaq was the strongest of the indices, as it continues its march towards 5,000. Crude oil prices fell by over 5% during the regular trading session, but recovered a bit in after-hours trading. The market is on pace to complete its fourth consecutive week of gains and close out the month of February with gains after suffering losses in January. ECONOMIC EVENTS: In the U.S., the Consumer Price Index fell 0.7% in January, with the core rate rising 0.2%, versus expectations for the headline CPI to be down 0.6% and the core rate to rise 0.1%. Initial jobless claims rose 31K to 313K in the week ended February 21, versus expectations for 290K first-time claims. Durable goods orders rose 2.8% in January, versus expectations for a 1.6% increase. The FHFA home price index rose 0.8% to 218.6 in December, versus expectations for an increase of 0.5%. COMPANY NEWS: The Federal Communications Commission voted 3 to 2 in favor of adopting new open Internet, or "net neutrality," rules. FCC Chairman Tom Wheeler has proposed that the FCC use its Title II authority to implement and enforce "bright-line" rules to ban paid prioritization and the blocking and throttling of lawful content and services. However, Wheeler said his proposal will "modernize" Title II, insuring there will be no rate regulation, no tariffs, and no last-mile unbundling. Major Internet Service Providers, including Verizon (VZ), AT&T (T), and Comcast (CMCSA), have opposed the rules, while Netflix (NFLX) has been a strong and vocal supporter of open Internet provisions... Shares of International Business Machines (IBM) slipped $1.94, or 1.19%, to $160.87 after Big Blue held its investor day meeting in NYC. At the meeting, IBM backed its fiscal year profit view but also said that the company now expects currency to impact revenue growth by over 6 points for the full year, which is greater than the impact previously provided based on January 16 spot rates. IBM also said it was shifting $4B into "strategic initiatives," including Big Data, the Cloud, mobile, social and security... Barnes & Noble (BKS) rose $1.67, or 6.89%, to $25.92 after announcing plans to split its Education business from its Retail and NOOK Digital businesses. The separation into two independent, publicly traded companies is anticipated to be completed by the end of August and is intended to be a tax-free distribution to shareholders, B&N noted. MAJOR MOVERS: Among the notable gainers was Emulex (ELX), which jumped $1.57, or 24.69%, to $7.93 after the company agreed to be acquired by Avago Technologies (AVGO) for $606M, or $8 per share in cash. Avago also rose $16.57, or 14.71%, to $129.25 after announcing the deal and reporting "beat and raise" quarterly results. Also higher was UIL Holdings (UIL), which gained $9.74, or 23.01%, to $52.07 after the company agreed to be acquired by Iberdrola USA to create a newly listed U.S. publicly-traded company. The proposed transaction implies total value per share to UIL shareholders of $52.75, including $10.50 per share paid in the form of cash, the companies said. Among the noteworthy losers was Clayton Williams (CWEI), which fell $11.41, or 17.77%, to $52.79 after the company suspended drilling operations in both of its core resource plays, citing low oil prices, and its shares were downgraded at Wunderlich. Also lower following their earnings reports were network solutions provider Inteliquent (IQNT), which dropped $3.05, or 17.33%, to $14.55, and electric weapons maker TASER (TASR), which slid $4.36, or 16.14%, to $22.68. INDEXES: The Dow fell 10.15, or -0.06%, to 18,214.42, the Nasdaq gained 20.75, or 0.42%, to 4,987.89, and the S&P 500 declined 3.12, or 0.15%, to 2,110.74.
16:13 EDTJCPJ.C. Penney down 5.6% after Q4 earnings miss expectations
16:12 EDTJCPJ.C. Penney sees FY15 comparable store sales up 3%-5%
Subscribe for More Information
16:11 EDTJCPJ.C. Penney ended year with liquidity of approximately $2.1B
For Q4, gross margin improved 540 basis points to 33.8% of sales, compared to 28.4% in the same quarter last year. Gross margin was positively impacted by significant improvement in the company's merchandise mix and margin on clearance sales over the prior year quarter.
16:10 EDTJCPJ.C. Penney reports Q4 adjusted EPS 0c, consensus 11c
Subscribe for More Information
15:30 EDTJCPNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Monster Beverage (MNST), consensus 59c... Ross Stores (ROST), consensus $1.11... Gap (GPS), consensus 74c... Autodesk (ADSK), consensus 24c... Universal Health Services (UHS), consensus $1.50... Southwestern Energy (SWN), consensus 50c... Ensco (ESV), consensus $1.36... J.C. Penney (JCP), consensus 11c... Nimble Storage (NMBL), consensus (14c)... Herbalife (HLF), consensus $1.22... Allscripts Healthcare (MDRX), consensus 9c... SBA Communications (SBAC), consensus 2c... Aruba Networks (ARUN), consensus 27c... Splunk (SPLK), consensus 4c... Air Lease (AL), consensus 61c... Ingram Micro (IM), consensus 99c... Weight Watchers (WTW), consensus 7c... Northern Oil and Gas (NOG), consensus 19c... Envision Healthcare (EVHC), consensus 36c... Infoblox (BLOX), consensus 5c... Live Nation (LYV), consensus (41c)... OmniVision (OVTI), consensus 29c... Bonanza Creek Energy (BCEI), consensus 27c.
15:23 EDTBMYBristol-Myers reports ALLY trial demonstrates 97% hepatitis C cure rates
Subscribe for More Information
14:29 EDTIQNTInteliquent revenue mix causing some anxiety, at BWS Financial
Subscribe for More Information
13:03 EDTJCPJ.C. Penney February weekly 9 straddle priced for 10.2% movement into Q4
Subscribe for More Information
12:48 EDTJCPEarnings Preview: J.C. Penney sees Q4 SSS at high end of 2%-4% view
Subscribe for More Information
12:01 EDTJCPAppeals court revives two claims by Macy's against J.C. Penney, Reuters says
A New York appeals court has revived two claims by Macy's (M) against J.C. Penney (JCP) that accuse J.C. Penney of contract interference and unfair competition related to a Martha Stewart contract, though the appeals court reaffirmed the prior decision that Macy's did not deserve punitive damages, reports Reuters, citing court statements. Reference Link
11:52 EDTJCPMacy's claims against J.C. Penney to be reinstated after appeal, Bloomberg says
11:09 EDTPBRStocks with call strike movement; LL PBR
Lumber Liquidators (LL) August 60 call option implied volatility decreased 5% to 59, Petrobras (PBR) July 7 call option implied volatility increased 2% to 67 according to IVolatility.
09:54 EDTPBRTransocean says well-positioned to deal with downturn in oil
Subscribe for More Information
09:41 EDTJNJHospira launches generic Remicade, WSJ says
Subscribe for More Information
08:35 EDTBMYBristol-Myers says BMS-966176 Phase IIa study met primary endpoint
Subscribe for More Information
08:03 EDTJNJJohnson & Johnson forms new health and wellness platform
Subscribe for More Information
07:36 EDTJCPJ.C. Penney volatility elevated into Q4 and outlook
J.C. Penney February weekly call option implied volatility is at 168, March weekly calls are at 91, April is at 55; compared to its 26-week average of 54 according to Track Data, suggesting large near term price movement into the expected release of Q4 results today.
07:25 EDTIQNTInteliquent sees FY15 revenue $215M-$230M, consensus $218.82M
Subscribe for More Information
07:24 EDTIQNTInteliquent reports Q4 EPS 30c, consensus 27c
Reports Q4 revenue $55.4M, consensus $53.87M.
07:19 EDTPBRMoody's to hold a teleconference on Petrobras downgrade
Teleconference discusses the rationale for the recent downgrades of Petrobras' rating to Ba2 is being held on February 26 at 10 am. Webcast Link
07:17 EDTPBRPetrobras call volatility flat into Q4 and capital outlook
Subscribe for More Information
06:52 EDTJNJPharmacyclics downgraded to Hold from Buy at WallachBeth
Subscribe for More Information
February 25, 2015
14:47 EDTJNJPharmacyclics could fetch as much as $19B in sale, FT says
Pharmacyclics (PCYC) is considering a sale that could fetch as much as $19B, reported Financial Times, citing people familiar with the matter who said Johnson & Johnson (JNJ) is exploring a potential deal for the company. The Fly notes that Bloomberg had a similar report, but its report said Pharmacyclics could fetch $17B-$18B in a sale. Reference Link
14:20 EDTPBRPetrobras taps JPMorgan to help sell $3B in assets, Reuters says
Subscribe for More Information
14:10 EDTJNJPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
13:08 EDTNKTRNektar volatility increases on start of Phase 3 study of NKTR-181
Nektar March call option implied volatility is at 87, April is at 78, May is at 74; compared to its 26-week average of 70 according to Track Data, suggesting large near term price movement on the announcement of the start of Phase 3 study of NKTR-181.
12:54 EDTJNJPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTJNJPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
09:36 EDTPBRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL HPQ PBR FSLR MRVL TSLA LVS ABX TWTR MGM
09:28 EDTNKTRNektar announces start of Phase 3 study of NKTR-181
Nektar announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of entry into the brain. The company said this slow rate of entry is designed to reduce the euphoria that can lead to the abuse of current opioid analgesics. SUMMIT-07 will evaluate the efficacy, safety and tolerability of NKTR-181 in patients with chronic low back pain who are also opioid-naïve. NKTR-181 is a new chemical entity that was created using Nektar's proprietary small molecule polymer conjugate technology. NKTR-181 has several potential differentiating properties that are inherent to the structure of the molecule, including a slow rate of entry into the CNS as measured by pupillometry and a plasma pharmacokinetic profile that supports twice-daily oral dosing. NKTR-181 is not a reformulation of a marketed opioid, which is a commonly-used method to attempt to prevent the manipulation of existing long-acting opioid drugs into more abusable forms. NKTR-181 has been granted has been granted Fast Track designation for the treatment of moderate to severe chronic pain by the U.S. Food and Drug Administration.
08:36 EDTBMYBristol-Myers announces data from Phase IIb BMS-663068 trial
Bristol-Myers Squibb Company announced data from a Phase IIb trial of investigational compound BMS-663068, designed as an HIV-1 attachment inhibitor, in treatment-experienced HIV-1 patients. In the study, which compared BMS-663068 to a pharmacoenhanced protease inhibitor, virologic response rates and immunologic reconstitution were similar across the BMS-663068 and Reyataz/ritonavir arms of the trial through 48 weeks. Specifically, 61-82% of BMS-663068 patients had HIV-1 RNA levels <50 c/mL, compared to 71% of Reyataz/ritonavir patients at week 48. HIV-1 RNA levels <50 c/mL typically indicate virus replication is undetectable. Treatment with BMS-663068 resulted in no dose response safety signals, no treatment discontinuations related to adverse events, and no treatment-related serious adverse events over the course of the trial. The most common AEs were headache and abdominal pain. Due to the positive results seen thus far, a Phase III clinical trial of the attachment inhibitor among heavily treatment-experienced patients began on Monday, February 23, 2015. For the purposes of the Phase III trial, heavily treatment-experienced patients are defined as individuals who can no longer formulate a viable regimen due to accumulation of drug resistance, past intolerabilities or antiretroviral contraindications. The Phase IIb study results, presented yesterday at the 22nd Conference on Retroviruses and Opportunistic Infections, highlight the novel mechanism of action of the investigational prodrug BMS-663068, which when converted into its active moiety BMS-626529, is designed to bind directly to the HIV gp120 protein, and prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell.
06:14 EDTVRTXPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
18:41 EDTPBRMoody's cuts Petrobras rating to 'Ba2' from 'Baa3', May cut further
Moody's Investors Service downgraded all ratings for Petrobras S.A., including a downgrade of the company's senior unsecured debt to Ba2 from Baa3, and assigned a Ba2 Corporate Family Rating to the company. Moody's also lowered the company's Baseline Credit Assessment to b2 from ba2. These rating actions reflect increasing concern about corruption investigations and liquidity pressures that might result from delays in delivering audited financial statements, as well as Moody's expectation that the company will be challenged to make meaningful reduction in its very high debt burden over the next several years. The ratings remain on review for downgrade. Reference Link
17:00 EDTNKTRNektar reports Q4 EPS (35c), consensus (36c)
Subscribe for More Information
11:36 EDTPBRStocks with call strike movement; GPRO PBR
GoPro (GPRO) July 50 call option implied volatility decreased 3% to 51, Petrobras (PBR) July 8 call option implied volatility decreased 1% to 66 according to IVolatility.
10:08 EDTGRMNOptions with decreasing implied volatility
Subscribe for More Information
07:46 EDTBMYJacobs Engineering awarded contract from Bristol-Myers
Jacobs Engineering Group (JEC) announced that it received a contract from Bristol-Myers Squibb Company (BMY) to provide architectural and engineering services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. The facility is being designed to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
06:48 EDTJCPPiper reiterates J.C. Penney as top pick for 2015
Piper Jaffray analyst Neely Tamminga reiterates J.C. Penney as a top pick for 2015 ahead of the retailer's year-end 2014 earnings report. Tamminga believes Penny's comp for February, the first month of its fiscal year, could be tracking up 4%. The analyst also thinks Penny management could express conviction in the retailer's plan to recapture share among moderate consumers on Thursday's earnings call. Tamminga has an Overweight rating on Penny with a $12 price target.
February 23, 2015
12:21 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
09:39 EDTPBRActive equity options trading on open
Subscribe for More Information
08:15 EDTBMYRigel Pharmaceuticals and Bristol-Myers announces R&D collaboration agreement
Rigel Pharmaceuticals (RIGL) and Bristol-Myers (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo and Yervoy. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:06 EDTBMYBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system’s activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel’s TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:01 EDTBMYBristol-Myers to acquire Flexus, potential total consideration may be $1.25B
Subscribe for More Information
February 22, 2015
12:51 EDTJNJJ&J considers Cordis sale with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
February 20, 2015
17:31 EDTJNJJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
16:48 EDTGRMNDow, S&P 500 finish week at record highs after Greek deal reached
Subscribe for More Information
16:03 EDTJNJOptions Update; February 20, 2015
Subscribe for More Information
10:01 EDTGRMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
08:19 EDTGRMNGarmin downgraded at Atlantic Equities
As previously reported, Atlantic Equities to Neutral from Overweight. The firm downgraded shares based on lack of catalysts and valuation. Price target lowered to $55.
07:23 EDTBMY, JNJAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
06:01 EDTGRMNGarmin downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
February 19, 2015
16:01 EDTPBROptions Update; February 19, 2015
iPath S&P 500 VIX Short-Term Futures down 70c to 30.11. Option volume leaders: AAPL TSLA TWTR AMAT PBR KO FB AXP NFLX according to Track Data.
14:41 EDTJCPJ.C. Penney volatility elevated into Q4 and outlook
Subscribe for More Information
11:11 EDTCATCaterpillar retail trends remain negative, says Wells Fargo
After Caterpillar reported earlier that its retail sales of machine declined 14% in the three month period ending in January, Wells Fargo noted that the trend worsened from December's 12% drop and that all regions reported declines. The firm believes retail trends remain negative for Caterpillar shares, on which it keeps a Market Perform rating.
09:59 EDTGRMNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
09:35 EDTPBROption volume leaders
Option volume leaders: AAPL TSLA TWTR MCD WMT PBR SPWR WFM GILD FB SCTY according to Track Data.
09:12 EDTGRMNOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTCATCaterpillar reports retail machines sales down 14% in three months end January
Caterpillar reported in a filing that its total retail machines sales were down 14% on a three month rolling basis in January. For reference, retail sales of machines were down 12% in the period ending in December and were down 10% in the period ending in November. The company reported world Resources Industries sales down 27% in the January period, which was down fom the 22% drop in the December end period. Construction Industries world sales were down 10%, worse than the 9% drop in the December period. Total Energy & Transportation Retail Sales were up 22% in the January end period, which was the same growth rate as seen in the December period.
07:20 EDTCATCaterpillar facing multiple federal investigations, WSJ says
Subscribe for More Information
07:18 EDTGRMNGarmin upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Garmin to Buy from Neutral. The firm upgraded shares citing the pullback post Q4 results. The analyst believes weakness is overdone and expects Garmin to be able to protect its market share in the activity tracking products priced at $200 and below and to continue to leverage its vertically integrated business model to respond to changing market dynamics. Price target is $60.
06:33 EDTGRMNGarmin upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
February 18, 2015
16:46 EDTJNJ, GRMNOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTPBROptions Update; February 18, 2015
Subscribe for More Information
12:36 EDTJNJAnalysts applaud cheaper than expected Boston Scientific settlement
Subscribe for More Information
12:31 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
10:59 EDTGRMNGarmin continues to look for opportunities for tuck-in acquisitions
10:43 EDTGRMNGarmin sees FY15 Automotive/Mobile revenue down about 15%
Subscribe for More Information
10:00 EDTJCPJ.C. Penney move higher attributed to real estate speculation
The move higher in shares of J.C. Penney (JCP) is being attributed to speculation the company may look to monetize its real estate assets. The speculation seems to be originating from a Jones Lang LaSalle (JLL) employee's webpage showing the retailer as a client. The JLL employee, Stephen Bridges, specializes in "assisting industrial users with the lease, purchase, and sale of real estate." It is not clear when Penny became a client of JLL. Shares of Penny rallied to a high of $8.50, and are trading up 16c to $8.29 in early trading. Reference Link
09:10 EDTGRMNOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTVRTXVertex data likely to show lung function improvement, says JMP Securities
Subscribe for More Information
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
07:04 EDTGRMNGarmin sees FY15 EPS about $3.10, consensus $3.24
Subscribe for More Information
07:03 EDTGRMNGarmin board authorizes repurchase of up to $300M of common stock
Subscribe for More Information
07:02 EDTGRMNGarmin board intends to recommend cash dividend of $2.04 per share
The board of directors intends to recommend to the shareholders for approval at the annual meeting to be held on June 5 a cash dividend in the amount of $2.04 per share, payable in four equal installments on dates to be determined by the Board.
07:01 EDTGRMNGarmin reports Q4 adjusted EPS 77c, consensus 78c
Reports Q4 revenue $803.31M, consensus $789.94M.
06:23 EDTCATCaterpillar discloses grand jury subpoena requesting financial information
Subscribe for More Information
February 17, 2015
17:15 EDTVNOVornado reports Q4 adj. FFO $1.36, consensus $1.23
Reports Q4 revenue $679.10M, consensus $677.44M.
16:29 EDTJNJ Boston Scientific announces settltement of merger agreement lawsuit
Subscribe for More Information
15:40 EDTGRMNGarmin technical comments ahead of results
Ahead of earnings the shares are moving higher, trading above the midpoint of the 1-year range. If the news meets or exceeds bullish expectations, next resistance levels are at $58.13, $60.19, and the 52-week high at $62.05. If the news fails to meet expectations, the following support levels could become downside objectives: $54.66, $52.89, and $50.08. A breakdown below $50 would snap the longer-term uptrend.
15:32 EDTGRMNNotable companies reporting before tomorrow's open
Subscribe for More Information
15:32 EDTVNONotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Devon Energy (DVN), consensus $1.05... Vornado Realty (VNO), consensus $1.23... Analog Devices (ADI), consensus 61c... FirstEnergy (FE), consensus 75c... CF Industries (CF), consensus $5.08... Agilent Technologies (A), consensus 41c... Cimarex Energy (XEC), consensus 82c... Flowserve (FLS), consensus $1.13... Fossil (FOSL), consensus $3.07... Rackspace (RAX), consensus 19c... Norwegian Cruise Line (NCLH), consensus 37c... Jack in the Box (JACK), consensus 87c... Cloud Peak Energy (CLD), consensus 7c... La-Z-Boy (LZB), consensus 38c... KAR Auction Services (KAR), consensus 29c... Owens & Minor (OMI), consensus 50c... Valmont Industries (VMI), consensus $1.65... Realty Income (O), consensus 66c.
14:21 EDTGRMNGarmin November volatility elevated into Q3 and outlook
Garmin March put option implied volatility is at 83, March is at 31, April is at 28; compared to its 26-week average of 27 according to Track Data, suggesting large price movement into the expected release of Q4 results on February 18.
13:03 EDTJCPJ.C. Penney volatility elevated into Q4 and outlook
Subscribe for More Information
07:04 EDTJNJGTx names Robert Wills as executive chairman
Subscribe for More Information
06:20 EDTPBRRolls-Royce vows to cooperate with Petrobras investigation, Financial Times says
Rolls-Royce (RYCEY) said it will co-operate with Brazilian authorities investigating allegations that it paid bribes to win a contract from Petrobras (PBR), reports the Financial Times. The company said, “We will take all necessary action to ensure compliance, including co-operating with authorities in any country.” Rolls-Royce had been accused of paying bribes in exchange for a $100M contract to provide “modules of energy generation” for the oil company’s platforms. Reference Link
<< 1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use